Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for HIV Reservoir Reduction (Lilac)
NCT02659306Phase 1Completed
- Sponsor
- McGill University Health Centre
- Start
- Sep 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liquid metformin (Aspargo Labs) in human immunodeficiency virus infection (HIV), sponsored by McGill University Health Centre. Primary endpoint: Decrease in the size of the HIV reservoir at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02659306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659306.